Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Zura Bio ( (ZURA) ).
On May 27, 2025, Zura Bio announced its participation in the Jefferies Global Healthcare Conference on June 4, 2025, where it will present a corporate overview and engage in one-on-one meetings with investors. This participation underscores Zura Bio’s commitment to advancing its position in the immunology sector, particularly with its lead product candidate, tibulizumab, currently in Phase 2 clinical trials for systemic sclerosis and hidradenitis suppurativa.
The most recent analyst rating on (ZURA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
Spark’s Take on ZURA Stock
According to Spark, TipRanks’ AI Analyst, ZURA is a Neutral.
Zura Bio’s overall stock score is driven by significant financial challenges, including no revenue generation and consistent losses despite a strong cash position and no debt. While technical indicators suggest some short-term bullish trends, the negative P/E ratio and lack of dividends underscore the valuation concerns. The company’s ability to generate revenue and improve operational efficiency will be crucial for future performance.
To see Spark’s full report on ZURA stock, click here.
More about Zura Bio
Zura Bio is a clinical-stage, multi-asset immunology company focused on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. The company’s pipeline includes product candidates targeting immune system imbalances to improve patient outcomes.
Average Trading Volume: 390,565
Technical Sentiment Signal: Sell
Current Market Cap: $63.11M
See more data about ZURA stock on TipRanks’ Stock Analysis page.